Provention Bio, Inc.

NasdaqGS:PRVB Voorraadrapport

Marktkapitalisatie: US$2.4b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Provention Bio Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Ashleigh Palmer

Algemeen directeur

US$2.3m

Totale compensatie

Percentage CEO-salaris29.79%
Dienstverband CEO6.5yrs
Eigendom CEO2.7%
Management gemiddelde ambtstermijn3.3yrs
Gemiddelde ambtstermijn bestuur3.8yrs

Recente managementupdates

Analyse-artikel • Feb 10

Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Recent updates

Seeking Alpha • Sep 19

Provention Bio appoints O'Brien as Chief People Officer

Provention Bio (NASDAQ:PRVB) has announced that the Co. has appointed Sarah O'Brien as Chief People Officer. "Sarah joins us at a key juncture, as we work to scale and grow Provention Bio while staying relentlessly focused on our purpose to intercept and prevent life-threatening autoimmune diseases," stated Ashleigh Palmer, Co-Founder and CEO.
Seeking Alpha • Sep 01

Provention Bio secures $125M term loan facility

Provention Bio (NASDAQ:PRVB) has secured a $125M term loan facility from Hercules Capital. The term loan facility provides for up to $125M of term loans in the aggregate, available to be funded in up to five tranches. The first tranche of $25M was drawn at closing. The biopharmaceutical company may draw the second tranche of $40M upon approval of teplizumab, subject to certain conditions. The third and fourth tranches will be available in an aggregate amount of up to $35M, subject to satisfaction of certain conditions, including achievement of certain milestones. The availability of the fifth tranche of up to $25M is subject to the approval of the lenders. CFO Thierry Chauche said, "This term loan facility significantly strengthens our balance sheet ahead of teplizumab's potential commercial launch and provides the Company with additional financial flexibility as we continue to work to change the landscape for patients with type 1 diabetes."
Seeking Alpha • Aug 12

Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating

BLA was delayed again to October/November due to FDA's request around PK data. Uncertainty around Teplizumab remains, and we are not a big fan of the FDA's recent request and delay in BLA. The company's warrant structure looks messy; PRVB has a long history of punishing investors with stock dilution. We downgrade the stock to sell from a hold rating. BLA delayed again to October/November The company provided additional color during the 2Q22 earnings call around information requests from the FDA; these are the key takeaways i) FDA information was requested from the FDA regarding incorporating ADA data in PK modeling of dosing regimen, ii) FDA's request resulted in the extended BLA decision date to Nov 17, iii) ADA does not impact the regimen for exposure or output of the model, and iv) there is no additional outstanding request from the agency at the moment. The rationale for the delay? FDA's rationale for the request during mid-June was to understand whether ADA levels would influence the recommended dosing adjustments set by the agency. As such, the company re-analyzed the data and found that the proposed dosing regimen remains unchanged by ADA levels and datapoints were consistent with the bioequivalency of legacy and commercial products. However, as the update was considered a major amendment, FDA indicated that they plan to discuss labeling and post-marketing requirements by Oct 17, 2022. What next? The key focus at this point is when investors will receive more clarity around the proc; during the Q2 earnings call, the company indicated that they would be able to provide additional regulatory updates during the Q3 earnings call planned around early Nov, based on their historical reporting timeline, as such, with the level of uncertainty, we remain on the sidelines. Even though there were rumors about label discussion, which indicates a higher likelihood of approval of the agent, during the Q2 earnings call, the company emphasized that the proposed label discussion will only continue if there are no deficiencies identified during the review period (FDA will communicate to the company by Oct 17). More messy warrants don't look good ...Today announced it has entered into a securities purchase agreement with institutional investors for the private placement of approximately $60 million of shares of its common stock and warrants to acquire 13,318,535 additional shares of its common stock (the "Warrants") (collectively, the "Securities"). The Warrants will be exercisable immediately upon issuance, in whole or in part, at an exercise price of $6.00 per share and will have a five-year term. Source: Provention Bio Announces $60 Million Private Placement As we flagged in our previous report, the company raised additional capital to finance its operation. We are not a fan of messy warrants as they can dilute the share value.
Seeking Alpha • Aug 03

Provention Bio Q2 2022 Earnings Preview

Provention Bio (NASDAQ:PRVB) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.50 (-8.7% Y/Y) and the consensus Revenue Estimate is $0.7M Over the last 3 months, EPS estimates have seen 2 upward revisions and 2 downward. Revenue estimates have seen 0 upward revisions and 2 downward.
Seeking Alpha • Jul 08

Provention Bio to raise $60M through private placement of securities

Provention Bio (NASDAQ:PRVB) has entered into a securities purchase agreement with institutional investors for the private placement of ~$60M of shares of its common stock and warrants to acquire 13,318,535 additional shares of its common stock. The private placement investors include Sessa Capital and Armistice Capital Master Fund Ltd. The warrants will be exercisable immediately at an exercise price of $6.00/share and will have a five-year term. The company anticipates aggregate gross proceeds from the offering will be approximately $60 million based on the offering price of $4.505 for each share of the Company's common stock plus one Warrant. Net proceeds from the private placement to fund expenses in preparation for the potential launch of teplizumab, to advance its clinical development candidates, as well as for working capital and other general corporate purposes. Offering is expected to close on or about July 13, 2022. Shares are up 5.02% after-hours.
Seeking Alpha • Jun 30

Provention Bio says FDA extends review period for co's teplizumab application to Nov. 17

Provention Bio (NASDAQ:PRVB) on Thursday said the U.S. FDA had extended its review period for the company's biologics license application for its lead drug candidate teplizumab by three months. The FDA is now set to decide on the application on or before Nov. 17. The FDA also informed PRVB that if no deficiencies are identified during the review period, then the regulator plans to inform the company on proposed labeling and any post-marketing requirements, if necessary, by Oct. 17. "We are committed to collaborating closely with the (FDA) as it completes its review," said PRVB CEO Ashleigh Palmer. PRVB stock earlier closed +2.3% at $4.
Seeking Alpha • Mar 31

Provention Bio (PRVB): BLA Accepted; Downgrading To A Hold

On March 26th, Provention Bio announced that the FDA accepted the BLA submission of Teplizumab for the delay of type 1 diabetes (T1D) indication for at-risk individuals. The goal date for PDUFA is August 17th. Until then, there is no meaningful catalyst, meaning the stock could trade lower for awhile. We stand by our previous view and remain bullish on Teplizumab’s success, and we believe re-entering near the catalyst date may be a wise low-risk strategy for investors. We maintain the target price of USD 10 (if no dilution happens). The key short-term risk would be a dilution of shares due to limited cash runway.
Seeking Alpha • Feb 04

Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes

We like the risk-reward of Provention Bio at this point and upgrading the rating to strong-buy from a buy. We accumulated a small option-sized position last week to play. The company announced its intention to re-submit the BLA for Teplizumab targeting type 1 diabetes in at-risk individuals. Approval of Teplizumab would represent a peak sales of USD 800-1.2B, and we view the probability of success to be around 80% at this point. Based on our valuation, the company is ~80% undervalued from its risk-adjusted valuation, and even after the recent 50% rally, there is more room to rally.
Analyse-artikel • Jan 11

Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analyse-artikel • Aug 26

Is Provention Bio (NASDAQ:PRVB) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Jul 30

Provention Bio: Blood (Glucose) In The Streets

It's been almost 18 months since I posted a comprehensive clinical overview of Provention Bio's main molecule teplizumab. I advised investors to avoid the stock due to an over-exuberance in potential for the At-Risk application of teplizumab. Shares have fallen ~60% since then, and in my opinion, now poses a high chance of long-term outperformance.
Analyse-artikel • Mar 17

How Much Of Provention Bio, Inc. (NASDAQ:PRVB) Do Insiders Own?

Every investor in Provention Bio, Inc. ( NASDAQ:PRVB ) should be aware of the most powerful shareholder groups...
Analyse-artikel • Feb 10

Need To Know: Provention Bio, Inc. (NASDAQ:PRVB) Insiders Have Been Buying Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Analyse-artikel • Jan 06

Provention Bio (NASDAQ:PRVB) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analyse-artikel • Dec 02

Is Provention Bio, Inc.'s (NASDAQ:PRVB) Shareholder Ownership Skewed Towards Insiders?

The big shareholder groups in Provention Bio, Inc. ( NASDAQ:PRVB ) have power over the company. Large companies usually...

Analyse CEO-vergoeding

Hoe is Ashleigh Palmer's beloning veranderd ten opzichte van Provention Bio's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Dec 31 2022US$2mUS$675k

-US$114m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$104m

Dec 31 2021US$2mUS$613k

-US$114m

Sep 30 2021n/an/a

-US$121m

Jun 30 2021n/an/a

-US$125m

Mar 31 2021n/an/a

-US$118m

Dec 31 2020US$2mUS$595k

-US$99m

Sep 30 2020n/an/a

-US$77m

Jun 30 2020n/an/a

-US$55m

Mar 31 2020n/an/a

-US$45m

Dec 31 2019US$4mUS$500k

-US$43m

Sep 30 2019n/an/a

-US$38m

Jun 30 2019n/an/a

-US$34m

Mar 31 2019n/an/a

-US$33m

Dec 31 2018US$584kUS$425k

-US$27m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$21m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$778kUS$290k

-US$9m

Compensatie versus markt: De totale vergoeding ($USD 2.27M ) Ashleigh } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.50M ).

Compensatie versus inkomsten: De vergoeding van Ashleigh is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ashleigh Palmer (59 yo)

6.5yrs
Tenure
US$2,266,108
Compensatie

Mr. Ashleigh W. Palmer, B.Sc., M.B.A., is Co-Founder, President, Chief Executive Officer and Director of Provention Bio, Inc. since October 4, 2016. Mr. Palmer served as Chief Executive Officer and Preside...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Ashleigh Palmer
Co-Founder6.5yrsUS$2.27m2.71%
$ 64.2m
Francisco Leon
Co-Founder & Chief Scientific Officer6.5yrsUS$1.16m1.13%
$ 26.8m
Eleanor Ramos
Chief Medical Officer3.3yrsUS$1.16m0.074%
$ 1.7m
Thierry Chauche
Chief Financial Officer1.3yrsUS$2.24mgeen gegevens
M. Yi
Chief Operations Officer1.3yrsgeen gegevensgeen gegevens
Robert Doody
Vice President of Investor Relationsno datageen gegevensgeen gegevens
Heidy King-Jones
Chief Legal Officer2.7yrsgeen gegevensgeen gegevens
Kaelan Hollon
Vice President of Corporate Communicationsno datageen gegevensgeen gegevens
Jason Levine
Vice President Marketingno datageen gegevensgeen gegevens
Sarah O'Brien
Chief People Officerless than a yeargeen gegevensgeen gegevens
Sherron Kell
Senior Vice President of Clinical Development3.7yrsgeen gegevensgeen gegevens
Jason Hoitt
Chief Commercial Officer3.3yrsUS$5.61m0%
$ 0
3.3yrs
Gemiddelde duur
46yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van PRVB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Ashleigh Palmer
Co-Founder6.5yrsUS$2.27m2.71%
$ 64.2m
Avery Catlin
Independent Director4.6yrsUS$168.04k0.021%
$ 499.6k
Nancy Wysenski
Independent Director2.9yrsUS$159.08k0%
$ 0
Wayne Pisano
Independent Chairman5yrsUS$198.36k0.0079%
$ 187.3k
John Jenkins
Independent Director2.7yrsUS$150.22k0%
$ 0
Rita Jain
Independent Directorless than a yeargeen gegevensgeen gegevens
3.8yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PRVB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2023/04/28 10:58
Aandelenkoers aan het einde van de dag2023/04/26 00:00
Inkomsten2022/12/31
Jaarlijkse inkomsten2022/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Provention Bio, Inc. wordt gevolgd door 10 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Alethia YoungCantor Fitzgerald & Co.
Taylor FeehleyChardan Capital Markets, LLC
Gbolahan Amusa BenzChardan Capital Markets, LLC